Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Market Cap: AU$4.5b

Telix Pharmaceuticals Future Growth

Future criteria checks 4/6

Telix Pharmaceuticals is forecast to grow earnings and revenue by 40.1% and 13.1% per annum respectively. EPS is expected to grow by 44.6% per annum. Return on equity is forecast to be 11.7% in 3 years.

Key information

40.1%

Earnings growth rate

44.60%

EPS growth rate

Biotechs earnings growth39.1%
Revenue growth rate13.1%
Future return on equity11.75%
Analyst coverage

Good

Last updated02 Jun 2026

Recent future growth updates

Recent updates

New Narrative • Mar 03

TLX... a Market's Overreaction or a Falling Knife?

So just for context to any investors happening upon this narrative... What does Telix actually do?
Analysis Article • Dec 31

The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%

The Telix Pharmaceuticals Limited ( ASX:TLX ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Aug 27

We Think You Can Look Beyond Telix Pharmaceuticals' (ASX:TLX) Lackluster Earnings

Telix Pharmaceuticals Limited's ( ASX:TLX ) stock was strong despite it releasing a soft earnings report last week. Our...
Analysis Article • Aug 08

Telix Pharmaceuticals Limited (ASX:TLX) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

ASX:TLX 1 Year Share Price vs Fair Value Explore Telix Pharmaceuticals's Fair Values from the Community and select...
Analysis Article • May 15

Here's Why Telix Pharmaceuticals (ASX:TLX) Can Manage Its Debt Responsibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Earnings and Revenue Growth Forecasts

ASX:TLX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,2968414012613
12/31/20271,14231565715
12/31/2026975483716
12/31/2025804-7-61-17N/A
9/30/20257362-372N/A
6/30/202566411-1323N/A
3/31/202557519432N/A
12/31/202451734527N/A
9/30/202446034827N/A
6/30/2024428331430N/A
3/31/202437621718N/A
1/1/20243334714N/A
9/30/2023276-14511N/A
6/30/2023238-3216N/A
3/31/2023167-52-28-21N/A
12/31/2022109-71-53-44N/A
9/30/202260-71-57-50N/A
6/30/202220-82-70-63N/A
3/31/202214-75-61-56N/A
12/31/20216-58-44-43N/A
9/30/20215-50-25-24N/A
6/30/20215-44-7-6N/A
3/31/20214-39-3-2N/A
12/31/20204-3512N/A
9/30/20203-29-9-9N/A
6/30/20202-25-19-18N/A
3/31/20202-20-16-15N/A
12/31/20192-20-17-16N/A
9/30/20192-16N/A-18N/A
6/30/20191-13N/A-20N/A
3/31/20191-12N/A-18N/A
12/31/20180-10N/A-15N/A
9/30/20180-9N/A-12N/A
6/30/2018N/A-7N/A-8N/A
3/31/2018N/A-6N/A-7N/A
12/31/2017N/A-5N/A-5N/A
12/31/2016N/A0N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.6%).

Earnings vs Market: TLX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TLX is expected to become profitable in the next 3 years.

Revenue vs Market: TLX's revenue (13.1% per year) is forecast to grow faster than the Australian market (6.2% per year).

High Growth Revenue: TLX's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TLX's Return on Equity is forecast to be low in 3 years time (11.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/06 01:48
End of Day Share Price 2026/06/05 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Madeleine WilliamsCanaccord Genuity